JPWO2020047510A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020047510A5 JPWO2020047510A5 JP2021510464A JP2021510464A JPWO2020047510A5 JP WO2020047510 A5 JPWO2020047510 A5 JP WO2020047510A5 JP 2021510464 A JP2021510464 A JP 2021510464A JP 2021510464 A JP2021510464 A JP 2021510464A JP WO2020047510 A5 JPWO2020047510 A5 JP WO2020047510A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- formula
- pharmaceutically acceptable
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 41
- 150000001875 compounds Chemical class 0.000 claims 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 10
- 230000000155 isotopic effect Effects 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 8
- 208000037026 Invasive Fungal Infections Diseases 0.000 claims 6
- 208000031888 Mycoses Diseases 0.000 claims 6
- 238000001802 infusion Methods 0.000 claims 6
- 229920000881 Modified starch Polymers 0.000 claims 5
- 235000019359 magnesium stearate Nutrition 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 4
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 3
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims 3
- 241000233866 Fungi Species 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 3
- 241000235527 Rhizopus Species 0.000 claims 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 239000012535 impurity Substances 0.000 claims 3
- 238000012423 maintenance Methods 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 3
- 229940069328 povidone Drugs 0.000 claims 3
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 claims 2
- 241000235389 Absidia Species 0.000 claims 2
- 241001071161 Asclepias Species 0.000 claims 2
- 241001225321 Aspergillus fumigatus Species 0.000 claims 2
- 201000007336 Cryptococcosis Diseases 0.000 claims 2
- 241001522864 Cryptococcus gattii VGI Species 0.000 claims 2
- 241000221204 Cryptococcus neoformans Species 0.000 claims 2
- 241000223218 Fusarium Species 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 241000235388 Mucorales Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 241000233870 Pneumocystis Species 0.000 claims 2
- 241000235402 Rhizomucor Species 0.000 claims 2
- 241000645784 [Candida] auris Species 0.000 claims 2
- 229940091771 aspergillus fumigatus Drugs 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 239000008363 phosphate buffer Substances 0.000 claims 2
- 201000000317 pneumocystosis Diseases 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 239000000454 talc Substances 0.000 claims 2
- 229910052623 talc Inorganic materials 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 241000293035 Apophysomyces Species 0.000 claims 1
- 241000293034 Apophysomyces elegans Species 0.000 claims 1
- 241000228212 Aspergillus Species 0.000 claims 1
- 241000228197 Aspergillus flavus Species 0.000 claims 1
- 241000335423 Blastomyces Species 0.000 claims 1
- 241000228405 Blastomyces dermatitidis Species 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 241000223203 Coccidioides Species 0.000 claims 1
- 241001522757 Coccidioides posadasii Species 0.000 claims 1
- 241000222175 Diutina rugosa Species 0.000 claims 1
- 241000427940 Fusarium solani Species 0.000 claims 1
- 241000228402 Histoplasma Species 0.000 claims 1
- 241000228404 Histoplasma capsulatum Species 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 241000235395 Mucor Species 0.000 claims 1
- 241000908234 Mucor indicus Species 0.000 claims 1
- 241001149962 Sporothrix Species 0.000 claims 1
- 241000228341 Talaromyces Species 0.000 claims 1
- 241000222126 [Candida] glabrata Species 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229940095731 candida albicans Drugs 0.000 claims 1
- 208000032343 candida glabrata infection Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- -1 glidant Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024094950A JP7793681B2 (ja) | 2018-08-31 | 2024-06-12 | 真菌感染症を処置するための化合物および方法 |
| JP2024094951A JP2024116313A (ja) | 2018-08-31 | 2024-06-12 | 真菌感染症を処置するための化合物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725971P | 2018-08-31 | 2018-08-31 | |
| US62/725,971 | 2018-08-31 | ||
| PCT/US2019/049223 WO2020047510A1 (en) | 2018-08-31 | 2019-08-30 | Compounds and methods for treating fungal infections |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024094951A Division JP2024116313A (ja) | 2018-08-31 | 2024-06-12 | 真菌感染症を処置するための化合物および方法 |
| JP2024094950A Division JP7793681B2 (ja) | 2018-08-31 | 2024-06-12 | 真菌感染症を処置するための化合物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021536446A JP2021536446A (ja) | 2021-12-27 |
| JPWO2020047510A5 true JPWO2020047510A5 (enExample) | 2022-08-15 |
| JP7522098B2 JP7522098B2 (ja) | 2024-07-24 |
Family
ID=69645369
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510464A Active JP7522098B2 (ja) | 2018-08-31 | 2019-08-30 | 真菌感染症を処置するための化合物および方法 |
| JP2024094951A Pending JP2024116313A (ja) | 2018-08-31 | 2024-06-12 | 真菌感染症を処置するための化合物および方法 |
| JP2024094950A Active JP7793681B2 (ja) | 2018-08-31 | 2024-06-12 | 真菌感染症を処置するための化合物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024094951A Pending JP2024116313A (ja) | 2018-08-31 | 2024-06-12 | 真菌感染症を処置するための化合物および方法 |
| JP2024094950A Active JP7793681B2 (ja) | 2018-08-31 | 2024-06-12 | 真菌感染症を処置するための化合物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210290644A1 (enExample) |
| EP (2) | EP4696315A2 (enExample) |
| JP (3) | JP7522098B2 (enExample) |
| KR (1) | KR20210088528A (enExample) |
| CN (2) | CN112996527B (enExample) |
| AR (1) | AR121477A1 (enExample) |
| AU (2) | AU2019328599B2 (enExample) |
| BR (1) | BR112021003878A2 (enExample) |
| CA (1) | CA3110860A1 (enExample) |
| EA (1) | EA202190590A1 (enExample) |
| IL (1) | IL281140A (enExample) |
| MX (1) | MX2021002444A (enExample) |
| TW (1) | TW202024058A (enExample) |
| WO (1) | WO2020047510A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022017653A2 (pt) | 2020-03-04 | 2022-10-18 | Amplyx Pharmaceuticals Inc | Uso de compostos no tratamento de infecções fúngicas |
| MX2022016179A (es) * | 2020-06-17 | 2023-04-20 | Amplyx Pharmaceuticals Inc | Compuestos y metodos para tratar infecciones fungicas. |
| WO2024229439A2 (en) * | 2023-05-03 | 2024-11-07 | The University Of Chicago | Inhibitors of nsun1- and nsun2-mediated active structures |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| DE10133394A1 (de) * | 2001-07-13 | 2003-01-30 | Merck Patent Gmbh | Flüssige Formulierung enthaltend Cetuximab |
| US7932272B2 (en) * | 2003-09-30 | 2011-04-26 | Eisai R&D Management Co., Ltd. | Antifungal agent containing heterocyclic compound |
| US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
| JPWO2012060448A1 (ja) * | 2010-11-05 | 2014-05-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗真菌剤としての併用医薬組成物 |
-
2019
- 2019-08-30 KR KR1020217009418A patent/KR20210088528A/ko active Pending
- 2019-08-30 JP JP2021510464A patent/JP7522098B2/ja active Active
- 2019-08-30 EP EP25225256.4A patent/EP4696315A2/en active Pending
- 2019-08-30 EP EP19853628.6A patent/EP3843769A4/en active Pending
- 2019-08-30 EA EA202190590A patent/EA202190590A1/ru unknown
- 2019-08-30 CA CA3110860A patent/CA3110860A1/en active Pending
- 2019-08-30 CN CN201980072614.1A patent/CN112996527B/zh active Active
- 2019-08-30 US US17/271,020 patent/US20210290644A1/en active Pending
- 2019-08-30 CN CN202510114568.4A patent/CN119818514A/zh active Pending
- 2019-08-30 BR BR112021003878-7A patent/BR112021003878A2/pt unknown
- 2019-08-30 AU AU2019328599A patent/AU2019328599B2/en active Active
- 2019-08-30 MX MX2021002444A patent/MX2021002444A/es unknown
- 2019-08-30 WO PCT/US2019/049223 patent/WO2020047510A1/en not_active Ceased
- 2019-09-02 AR ARP190102493A patent/AR121477A1/es unknown
- 2019-09-02 TW TW108131566A patent/TW202024058A/zh unknown
-
2021
- 2021-02-28 IL IL281140A patent/IL281140A/en unknown
-
2024
- 2024-06-12 JP JP2024094951A patent/JP2024116313A/ja active Pending
- 2024-06-12 JP JP2024094950A patent/JP7793681B2/ja active Active
-
2025
- 2025-07-30 AU AU2025210781A patent/AU2025210781A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519288A5 (enExample) | ||
| JP2018510178A5 (enExample) | ||
| JP7793681B2 (ja) | 真菌感染症を処置するための化合物および方法 | |
| US20230364067A1 (en) | Antifungal agents with enhanced activity in acidic ph | |
| JPH11504931A (ja) | 抗真菌組成物 | |
| JPWO2020047510A5 (enExample) | ||
| Van Cutsem | In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents. | |
| JP2022524819A (ja) | カプシド集合調節剤固体製剤 | |
| TWI888580B (zh) | 用於治療真菌感染之化合物及方法 | |
| EP3917534A1 (en) | Triterpenoid antifungals for the treatment of fungal osteo-articular infections | |
| CN112451678B (zh) | HMG-CoA还原酶抑制剂-维D的药物组合物及用途 | |
| HK40050392B (zh) | 用於治疗真菌感染的化合物和方法 | |
| RU2024102382A (ru) | Кишечнорастворимые лекарственные формы для перорального применения с контролируемым высвобождением | |
| RU2020102015A (ru) | Кишечнорастворимые лекарственные формы для перорального применения с контролируемым высвобождением | |
| WO2021053564A1 (en) | Pharmaceutical composition comprising remogliflozin or salt or ester thereof and teneligliptin or salt thereof | |
| JPWO2021178406A5 (enExample) | ||
| HK40109129A (zh) | 在酸性ph值下具有经增强活性的抗真菌剂 | |
| EA047126B1 (ru) | Противогрибковое средство для лечения или профилактики инфекции вульвовагинального кандидоза | |
| HK40062374A (en) | Triterpenoid antifungals for the treatment of fungal osteo-articular infections | |
| HK40062374B (en) | Triterpenoid antifungals for the treatment of fungal osteo-articular infections | |
| HK40030410B (en) | Antifungal agents with enhanced activity in acidic ph | |
| NZ740967B2 (en) | Composition for treatment of infertility in a female subject | |
| JPWO2022251441A5 (enExample) |